Perosphere and Daiichi Sankyo enter into a clinical trial agreement
26 April 2013 | By Daiichi Sankyo
Daiichi Sankyo to support and co-sponsor phase 1 Clinical Study...
List view / Grid view
26 April 2013 | By Daiichi Sankyo
Daiichi Sankyo to support and co-sponsor phase 1 Clinical Study...
25 April 2013 | By Daiichi Sankyo
The first patient has been enrolled in two pivotal phase 3 clinical trials of nimotuzumab...
22 April 2013 | By Daiichi Sankyo
Daiichi Sankyo announced that its subsidiary, Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd., has begun marketing silodosin...
8 April 2013 | By Daiichi Sankyo
GHIT Fund aims to promote the R&D of new medicines, vaccines & diagnostics in Japan...
25 March 2013 | By Daiichi Sankyo
Approval to manufacture and market the osteoporosis treatment...
16 March 2013 | By Daiichi Sankyo
Results of the PRASFIT-ACS study...
4 March 2013 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced the following organizational changes taking place from April 1, 2013...
20 February 2013 | By Daiichi Sankyo
DPT-IPV vaccine for prevention of Diphtheria, Pertussis, Tetanus, and acute Poliomyelitis...
14 February 2013 | By Daiichi Sankyo
Daiichi Sankyo will establish a new company, Orphan Disease Treatment Institute Co., Ltd...
16 January 2013 | By Daiichi Sankyo
Daiichi Sankyo and Ranbaxy announced their intention to integrate their business operations in Thailand...
15 January 2013 | By Daiichi Sankyo
“We are encouraged by these findings..."
8 January 2013 | By Daiichi Sankyo
Daiichi Sankyo & Amplimmune have entered into a broad strategic collaboration...
25 October 2012 | By Daiichi Sankyo
Edoxaban is an investigational, once daily, novel oral factor Xa inhibitor...
21 September 2012 | By Daiichi Sankyo
Data from the PRASFIT-ACS study...
26 August 2012 | By Eli Lilly and Company
Study did not meet primary objective of demonstrating prasugrel superiority over clopidogrel in this patient population...